Today, a brief rundown of news involving Karyopharm Therapeutics and Amgen, as well as updates from BridgeBio Oncology Therapeutics, Evommune, Encoded Therapeutics and Schrödinger that you may have missed.
Cash-strapped Karyopharm Therapeutics has reached a deal with creditors that’ll give the company extra time to make a $15.8 million debt payment that came due on Thursday. According to a regulatory filing, a group of lenders, noteholders and royalty investors will hold off on taking action through Oct. 15, giving Karyopharm a little over a month to negotiate, pursue strategic alternatives or find additional financing. Karyopharm agreed to pay a $20 million fee in the form of newly issued convertible stock as part of the deal. Though lengthier financial relief would’ve been “most ideal,” the agreement “at least buys the company time,” wrote RBC Capital Markets analyst Brian Abrahams. Karyopharm is waiting to see whether U.S. regulators will accept an approval application for its multiple myeloma drug Xpovio in myelofibrosis. — Ben Fidler
A combination of Amgen’s Imdelltra and AstraZeneca’s Imfinzi helped people with first-line, extensive small-cell lung cancer live longer than Imfinzi alone in a Phase 3 trial. Amgen didn’t provide specifics in a Tuesday statement, but said a trial monitoring committee detected a survival benefit among Imdelltra-Imfinzi recipients at an early data check, along with statistically significant improvements on measures of tumor progression and drug responses. Imdelltra is currently approved as a single agent for people whose disease gets worse following chemotherapy, and generated about $627 million in sales last year. Approval in the first-line setting could yield “a significant expansion” of the drug’s sales potential, wrote William Blair analyst Myles Minter. Amgen will discuss the data with regulators. — Jonathan Gardner
Evommune’s experimental drug EVO756 missed the main goal of a Phase 2 trial in atopic dermatitis, failing to significantly reduce the size or severity of skin lesions in atopic dermatitis patients when compared to a placebo, the company said Tuesday. The setback marks the second recent negative readout for EVO756, which fell short in a trial in chronic spontaneous urticaria in June. Evommune has lost more than 40% of its market value since going public last year. EVO756’s struggles have led investors to shift their attention to another therapy, EVO301, that’s also in testing for atopic dermatitis, wrote Oppenheimer analyst Kostas Biliouris. That treatment “looks interesting,” as it might help people who don’t respond to Dupixent, he wrote. — Jonathan Gardner
Shares of BridgeBio Oncology Therapeutics have fallen by more than one-third since the company announced Tuesday it’s scaling back development for two KRAS-blocking drugs. BridgeBio dropped plans to test one drug, BBO-8520, in the first-line non-small cell lung cancer. It also deprioritized a breast cancer trial for a second therapy known as BBO-10203. BridgeBio made those decisions to focus resources on studies with “the highest probability of success and greatest potential benefit for patients,” among them a combination trial in second-line lung cancer. While those moves were “prudent” financially, they nonetheless eliminated a “large potential opportunity,” wrote Leerink Partners analyst Andrew Berens. — Jonathan Gardner
Encoded Therapeutics has raised a $275 million Series F round to advance a pair of gene therapies for neurological disorders, the company said. Encoded’s most advanced candidate, a gene therapy dubbed ETX-101, showed in an early-stage trial the potential to lower the frequency of seizures and improve cognition in children with the rare genetic condition Dravet syndrome. A second program called ETX-301 is in preclinical development for chronic pain from post-amputation neuromas, a thickening of nerve tissue that occurs after limb loss. Led by investors including GV, Arch Venture Partners and RTW Investments, the funding will also help Encoded boost its manufacturing capabilities. — Gwendolyn Wu
A biotech startup launched Wednesday by Schrödinger, RA Capital and New Enterprise Associates is setting out with a goal to develop drugs for inflammatory diseases. Called Tectora Therapeutics, the young company is starting up with $55 million to take forward two Schrödinger small molecules, called SDGR-4594 and SDGR-8139, into human testing. Multiple startups linked to Schrödinger have signed large deals with drugmakers, among them Nimbus Therapeutics, Morphic Therapeutic and Ajax Therapeutics. Nimbus sold some drug programs to Gilead Sciences and Takeda, while Morphic and Ajax were acquired by Eli Lilly. — Gwendolyn Wu
Facts Only
* Karyopharm Therapeutics reached a deal with creditors regarding a $15.8 million debt payment due on Thursday.
* A group of lenders, noteholders, and royalty investors will hold action through October 15 for Karyopharm.
* Karyopharm agreed to pay a $20 million fee in the form of newly issued convertible stock as part of the deal.
* Amgen's Imdelltra and AstraZeneca's Imfinzi combination showed a survival benefit in a Phase 3 trial for small-cell lung cancer.
* Evommune's drug EVO756 missed its main goal in a Phase 2 trial for atopic dermatitis compared to placebo.
* BridgeBio Oncology Therapeutics dropped plans to test BBO-8520 in first-line non-small cell lung cancer and deprioritized the BBO-10203 breast cancer trial.
* Encoded Therapeutics raised $275 million in a Series F round.
* Encoded's ETX-101 showed potential to lower seizure frequency and improve cognition in children with Dravet syndrome in an early-stage trial.
* Schrödinger launched Tectora Therapeutics with $55 million to advance SDGR-4594 and SDGR-8139 into human testing.
Executive Summary
Full Take
The narrative presents a mosaic of corporate maneuvering, where immediate financial stabilization is balanced against long-term therapeutic uncertainty. Karyopharm's situation illustrates the tension between short-term solvency and regulatory milestones; the structure of the creditor agreement prioritizes buying time over immediate maximal relief, suggesting that external pressures dictate the timeline for internal strategic pivots. This dynamic is mirrored in the clinical landscape, where success in one area (Amgen’s data) suggests potential expansion, while setbacks elsewhere (Evommune’s EVO756) force a re-evaluation of therapeutic pathways, as evidenced by the investor pivot toward alternative candidates like EVO301. The shifts at BridgeBio reflect a classic risk management strategy: trimming lower-probability bets to maximize potential returns in areas with proven traction, indicating that financial prudence often necessitates sacrificing large speculative opportunities. Finally, the emergence of Encoded and Schrödinger highlights the bifurcation in biotech innovation—one path focusing on established genetic disorders and pain management (Encoded) and another focusing on novel inflammatory disease targets through small molecule development (Schrödinger). The pattern suggests that successful navigation requires recognizing which uncertainties are negotiable (like debt timelines) and which require absolute commitment (like clinical trial execution), forcing an acknowledgment that risk profiles differ fundamentally across therapeutic modalities.
Bridge questions: How do the market reactions to positive data (Amgen) compare to the reaction to negative reads (Evommune), and what does this reveal about investor tolerance for uncertainty in oncology versus dermatology? If Karyopharm successfully navigates the debt agreement, what will be the most significant strategic alternative pursued by management within the next quarter? How do the diverse investment strategies observed at BridgeBio contrast with the potential impact of Encoded's successful gene therapy pipeline on broader neurological health metrics?